Eurobio Scientific has signed a strategic agreement with Biovica, a company specializing in cancer monitoring, to distribute DiviTum® TKa in key European markets, including DACH, UK, FR and Benelux.

This collaboration covers 60% of the European market potential and strengthens Eurobio Scientific’s oncology diagnostics offering. DiviTum® TKa is a blood-based biomarker test that monitors and predicts treatment response in hormone receptor-positive metastatic breast cancer.

By measuring thymidine kinase activity (TKa)—a key indicator of cell proliferation—the test can detect disease progression months before imaging. It provides valuable insights into a patient’s response to therapy, helping healthcare providers determine whether patients are benefiting from CDK4/6 inhibitor treatment and who may benefit from continuing therapy. 

By partnering with Biovica, Eurobio Scientific expands its portfolio, offering oncologists across Europe a broader range of cutting-edge diagnostic solutions. 

“We see great potential in DiviTum TKa, which will allow us to sell a broader range of tests to our established network of breast oncologists in the selected countries. It complements our oncology portfolio very well and our strong oncology sales force now has an even more comprehensive offering,” said Denis Fortier, Chairman and CEO of Eurobio Scientific.